Can-Fite BioPharma's shares decline after reverse split approval
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 29 Dec 25
Can-Fite BioPharma Ltd. shares fell by 15.19% as the stock crossed below the 5-day SMA, reflecting a negative market reaction.
The decline follows the company's announcement of a 1-for-3,000 reverse stock split approved by its board, aimed at enhancing share price to meet listing requirements. This decision, effective January 2, 2026, may lead to short-term volatility as investors react to the anticipated new share price, despite the company's efforts to optimize its capital structure and attract more investments.
The market's cautious response indicates that while the reverse split is intended to improve market performance, it has led to immediate concerns about the stock's future valuation and investor confidence.
Analyst Views on CANF
Wall Street analysts forecast CANF stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CANF is 2.50 USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 4.100
Low
2.50
Averages
2.50
High
2.50
Current: 4.100
Low
2.50
Averages
2.50
High
2.50
About CANF
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
